Jun, 2019
Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease
JAPANESE JOURNAL OF RADIOLOGY
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- Volume
- 37
- Number
- 6
- First page
- 481
- Last page
- 486
- Language
- English
- Publishing type
- Research paper (scientific journal)
- DOI
- 10.1007/s11604-019-00821-7
- Publisher
- SPRINGER
PURPOSE: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). MATERIALS AND METHODS: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2, in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. RESULTS: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m2. The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. CONCLUSION: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.
- Link information
- ID information
-
- DOI : 10.1007/s11604-019-00821-7
- ISSN : 1867-1071
- eISSN : 1867-108X
- Pubmed ID : 30941617
- Web of Science ID : WOS:000469834600006